What is Vocinti (Vonoprazan)?
Vocinti is the brand name for vonoprazan, a potassium-competitive acid blocker (PCAB).
Unlike PPIs, it directly blocks gastric acid secretion with rapid onset and longer duration of action.
Approved for GERD, erosive esophagitis, peptic ulcers, NSAID-induced ulcers, and H. pylori eradication therapy.
Clinical Uses in Gastroenterology
GERD & Acid Reflux: Provides faster symptom relief and mucosal healing compared to PPIs.
Peptic Ulcers: Effective in treating gastric and duodenal ulcers, including those caused by NSAIDs.
Helicobacter pylori Eradication: Used in combination with antibiotics (amoxicillin + clarithromycin) for improved eradication rates.
Maintenance Therapy: Prevents relapse of healed erosive esophagitis with lower recurrence rates.
Risks & Considerations
Side effects: Diarrhea, constipation, abdominal pain, headache.
Drug interactions: May interact with certain antibiotics and anticoagulants.
Long-term safety: Still under study compared to decades of PPI data.
